Technical Analysis for VCEL - Vericel Corporation
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing High | Bullish | -0.19% | |
| Stochastic Reached Overbought | Strength | -0.19% | |
| Wide Bands | Range Expansion | -0.19% | |
| Overbought Stochastic | Strength | -0.19% | |
| Up 3 Days in a Row | Strength | -0.19% | |
| Wide Bands | Range Expansion | 2.36% | |
| Spinning Top | Other | 8.05% | |
| Outside Day | Range Expansion | 8.05% | |
| Wide Bands | Range Expansion | 8.05% | |
| NR7 | Range Contraction | 8.90% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | 2 minutes ago |
| New 52 Week High | 2 minutes ago |
| Up 1% | 2 minutes ago |
| 60 Minute Opening Range Breakout | about 22 hours ago |
| Up 2% | about 23 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/07/2024
Vericel Corporation Description
Vericel Corporation, a commercial-stage biopharmaceutical company, focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two autologous cell therapy products in the United States, including Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. The company is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company, formerly known as Aastrom Biosciences, Inc., was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Stem Cell Cell Therapy Heart Failure Knee Burns Cardiomyopathy Myopathy Cartilage Osteochondritis Dissecans Severe Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 57.81 |
| 52 Week Low | 32.31 |
| Average Volume | 398,320 |
| 200-Day Moving Average | 46.97 |
| 50-Day Moving Average | 45.61 |
| 20-Day Moving Average | 49.61 |
| 10-Day Moving Average | 54.34 |
| Average True Range | 2.34 |
| RSI (14) | 72.45 |
| ADX | 32.21 |
| +DI | 39.17 |
| -DI | 15.36 |
| Chandelier Exit (Long, 3 ATRs) | 50.79 |
| Chandelier Exit (Short, 3 ATRs) | 47.53 |
| Upper Bollinger Bands | 59.74 |
| Lower Bollinger Band | 39.48 |
| Percent B (%b) | 0.88 |
| BandWidth | 40.84 |
| MACD Line | 3.20 |
| MACD Signal Line | 2.56 |
| MACD Histogram | 0.6333 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 60.27 | ||||
| Resistance 3 (R3) | 59.97 | 58.65 | 59.77 | ||
| Resistance 2 (R2) | 58.65 | 57.89 | 58.81 | 59.60 | |
| Resistance 1 (R1) | 57.96 | 57.41 | 58.30 | 58.26 | 59.44 |
| Pivot Point | 56.64 | 56.64 | 56.82 | 56.80 | 56.64 |
| Support 1 (S1) | 55.95 | 55.88 | 56.30 | 56.26 | 55.08 |
| Support 2 (S2) | 54.63 | 55.40 | 54.79 | 54.92 | |
| Support 3 (S3) | 53.94 | 54.63 | 54.75 | ||
| Support 4 (S4) | 54.25 |
